UCB's Vimpat scores US monotherapy approval, Europe to follow?
This article was originally published in Scrip
Executive Summary
UCB's anti-epileptic agent Vimpat (lacosamide) has been granted approval in the US as a monotherapy for partial-onset seizures (POS).